Clinical efficacy and tolerability of valacyclovir versus acyclovir in treatment of herpes zoster

Background: acyclovir, a specific and selective inhibitor ofreplication of herpesviridae family, has well documented efficacy for speedy rash healing and decreasing pain of herpes zoster.limited oral bioavailability of acyclovir requires frequent dosing.valacyclovir is rapidly and almost completely converted toacyclovir in vivo and gives three to fivefold increase in acyclovirbio availability. the aim of this study was to assess the clinicalefficacy, safety and tolerability of oral valacyclovir versus standardoral acyclovir in the treatment of herpes zoster.methods: a blind randomized prospective study was performed during may 2007 to august 2007 in midnapore medical college.immunocompetent patients, aged .40yrs presenting with herpeszoster within 72 hours after onset of rash were enrolled and randomized to receive one of the following treatments: 1000mg of valacyclovir thrice daily for 7 days or acyclovir 800 mg 5times daily for 7 days. a total of 60 patients were included and randomized to receive either valacyclovir (n=30) or acyclovir(n=30) and they were evaluated at 8 days, 15 days and 29 days,respectively.results: a statistically significant reduction of skin lesion andzoster associated pain were noticed in valacyclovir compared to acyclovir group. however, presence of post herpetic neuralgiaon the 29th day was less in acyclovir compared to valacyclovir group (70.0% vs. 83.3%, p>0.05). only one patient on valacyclovirand two patients on acyclovir complained of nausea and mild abdominal pain.conclusion: we conclude that for the management of herpeszoster, valacyclovir might be superior to acyclovir in respect toreduction of skin lesions and pain.